Cristina Tarango, MD
- Medical Director, Hemophilia Treatment Center
- Professor, UC Department of Pediatrics
- cristina.tarango@cchmc.org
- Board Certified
About
Biography
As a pediatric hematologist, I treat children with conditions such as hemophilia, von Willebrand disease, thrombosis (blood clots) and other blood conditions. I try to treat each patient the way I would want my family members to be cared for. It’s very important for patients and families to take an active role in their care and share in the decision-making.
I was influenced in my career choice by a wonderful pediatrician who cared for me when I was growing up. After I became a pediatrician, I chose the field of hematology because it’s so diverse and interesting. At Cincinnati Children’s, I enjoy working with our dedicated group of physicians as well as our excellent nurse care managers, social workers, child life specialists and other professionals who are so committed to supporting children with blood disorders.
In addition to patient care, I conduct research. My studies are focused on gaining a better understanding of thrombosis and its management in children. I am also involved with studies assessing different treatments for hemophilia, as well as evaluating the immune system in patients with hemophilia, both with and without inhibitors. Inhibitors are antibodies that can prevent treatments from working, which makes it more difficult to stop a bleeding episode.
Outside the hospital, I love spending time with my husband and daughter. I also enjoy traveling, reading and volunteering when I can.
MD: Stanford University School of Medicine, Stanford, CA, 2003.
Residency: Yale-New Haven Hospital, New Haven, CT, 2006.
Fellowship: University of Texas Southwestern Medical Center Dallas, Dallas, TX, 2009.
Certification: Pediatrics, 2006; Pediatric Hematology Oncology, 2011.
Interests
Pediatric bleeding disorders and thrombosis; quality improvement; medical education
Services and Specialties
Cancer and Blood Diseases, Thrombosis, Epidermolysis Bullosa EB, Hemophilia
Interests
Pediatric bleeding disorders and thrombosis; quality improvement; medical education
Research Areas
Hematology, Cancer and Blood Diseases
Additional Languages
Spanish
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa. Orphanet Journal of Rare Diseases. 2023; 18:38.
Use and Outcomes of Secondary Anticoagulation in Patients <21 Years Old Following Completion of a Primary Course of Anticoagulation for Treatment of Acute Provoked VTE: Findings from the Multinational Kids-DOTT Trial. Blood. 2023; 142:1275.
Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A. Blood. 2023; 142:506.
Emicizumab Use in Infancy: A Survey of United States Pediatric Hemophilia Treatment Center Medical Directors. Blood. 2023; 142:1242.
OC 38.4 Transient Antiphospholipid Antibodies, Antiphospholipid Syndrome and Clinical Outcomes in Patients <21 Years Old with Provoked Venous Thromboembolism: Analysis from the Kids-DOTT Multinational Trial. Research and Practice in Thrombosis and Haemostasis. 2023; 7:100519.
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders. Expert Review of Hematology. 2023; 16:39-54.
Iron status and burden of anemia in children with recessive dystrophic epidermolysis bullosa. Pediatric Dermatology. 2023; 40:288-293.
Improving bleeding disorder treatment log adherence: An application of the information-motivation-behavioral skills model. Haemophilia. 2023; 29:180-185.
Obesity and Race As Determinates of Plasma Von Willebrand and Factor VIII Levels. Blood. 2022; 140:5593-5594.
U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics. Blood. 2022; 140:63-64.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey